Geisinger’s DNA sequencing effort will launch with a 1,000-patient pilot program during the next six months. Eventually, the health system intends to recommend DNA sequencing services to every patient across its facilities in Pennsylvania and southern New Jersey.
The decision builds on Geisinger’s existing genomics research efforts, including its MyCode Community Health Initiative, which enrolled 200,000-plus patients to donate DNA samples for precision medicine studies.
Dr. Feinberg said DNA sequencing has the potential to provide patients with preventive healthcare — rather than “responsive sick care” — similar to standard screenings such as mammograms, colonoscopies and cholesterol checks.
“Understanding the genome warning signals of every patient will be an essential part of wellness planning and health management,” Dr. Feinberg said. “Geisinger patients will be able to work with their family physician to modify their lifestyle and minimize risks that may be revealed.”
More articles on data analytics & precision medicine:
A direct-to-consumer DNA testing service fails to distinguish dog DNA from human DNA
Lancaster General Health partners with private equity firm to launch $300M precision medicine fund
7 most interesting questions NIH Director Dr. Francis Collins answered during his Reddit AMA
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
